Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.
Identifieur interne : 000B42 ( PubMed/Curation ); précédent : 000B41; suivant : 000B43Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.
Auteurs : Emmanuel Itti [France] ; Gabriel Villafane ; Zoulikha Malek ; Pierre Brugières ; Daniela Capacchione ; Laurent Itti ; Patrick Maison ; Pierre Cesaro ; Michel MeignanSource :
- Nuclear medicine communications [ 1473-5628 ] ; 2009.
English descriptors
- KwdEn :
- Administration, Cutaneous, Dopamine Plasma Membrane Transport Proteins (analysis), Dopamine Plasma Membrane Transport Proteins (metabolism), Dose-Response Relationship, Drug, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neostriatum (drug effects), Neostriatum (physiopathology), Nicotine (administration & dosage), Nicotine (therapeutic use), Parkinson Disease (diagnostic imaging), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Regression Analysis, Time Factors, Tomography, Emission-Computed, Single-Photon, Tropanes.
- MESH :
- chemical , administration & dosage : Nicotine.
- chemical , analysis : Dopamine Plasma Membrane Transport Proteins.
- chemical , metabolism : Dopamine Plasma Membrane Transport Proteins.
- diagnostic imaging : Parkinson Disease.
- drug effects : Neostriatum.
- drug therapy : Parkinson Disease.
- metabolism : Parkinson Disease.
- physiopathology : Neostriatum.
- chemical , therapeutic use : Nicotine.
- Administration, Cutaneous, Dose-Response Relationship, Drug, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Regression Analysis, Time Factors, Tomography, Emission-Computed, Single-Photon, Tropanes.
Abstract
Nicotine therapy might improve the course of Parkinson's disease. This observational study evaluated the performance of dopamine transporter imaging in follow-up patients under nicotine therapy.
DOI: 10.1097/MNM.0b013e32832cc204
PubMed: 19451839
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B82
Links to Exploration step
pubmed:19451839Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.</title><author><name sortKey="Itti, Emmanuel" sort="Itti, Emmanuel" uniqKey="Itti E" first="Emmanuel" last="Itti">Emmanuel Itti</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine, H. Mondor Hospital, AP-HP, Paris 12 University, Créteil, France. emmanuel.itti@hmn.aphp.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, H. Mondor Hospital, AP-HP, Paris 12 University, Créteil</wicri:regionArea></affiliation></author><author><name sortKey="Villafane, Gabriel" sort="Villafane, Gabriel" uniqKey="Villafane G" first="Gabriel" last="Villafane">Gabriel Villafane</name></author><author><name sortKey="Malek, Zoulikha" sort="Malek, Zoulikha" uniqKey="Malek Z" first="Zoulikha" last="Malek">Zoulikha Malek</name></author><author><name sortKey="Brugieres, Pierre" sort="Brugieres, Pierre" uniqKey="Brugieres P" first="Pierre" last="Brugières">Pierre Brugières</name></author><author><name sortKey="Capacchione, Daniela" sort="Capacchione, Daniela" uniqKey="Capacchione D" first="Daniela" last="Capacchione">Daniela Capacchione</name></author><author><name sortKey="Itti, Laurent" sort="Itti, Laurent" uniqKey="Itti L" first="Laurent" last="Itti">Laurent Itti</name></author><author><name sortKey="Maison, Patrick" sort="Maison, Patrick" uniqKey="Maison P" first="Patrick" last="Maison">Patrick Maison</name></author><author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name></author><author><name sortKey="Meignan, Michel" sort="Meignan, Michel" uniqKey="Meignan M" first="Michel" last="Meignan">Michel Meignan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19451839</idno><idno type="pmid">19451839</idno><idno type="doi">10.1097/MNM.0b013e32832cc204</idno><idno type="wicri:Area/PubMed/Corpus">000B82</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B82</idno><idno type="wicri:Area/PubMed/Curation">000B42</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B42</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.</title><author><name sortKey="Itti, Emmanuel" sort="Itti, Emmanuel" uniqKey="Itti E" first="Emmanuel" last="Itti">Emmanuel Itti</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine, H. Mondor Hospital, AP-HP, Paris 12 University, Créteil, France. emmanuel.itti@hmn.aphp.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, H. Mondor Hospital, AP-HP, Paris 12 University, Créteil</wicri:regionArea></affiliation></author><author><name sortKey="Villafane, Gabriel" sort="Villafane, Gabriel" uniqKey="Villafane G" first="Gabriel" last="Villafane">Gabriel Villafane</name></author><author><name sortKey="Malek, Zoulikha" sort="Malek, Zoulikha" uniqKey="Malek Z" first="Zoulikha" last="Malek">Zoulikha Malek</name></author><author><name sortKey="Brugieres, Pierre" sort="Brugieres, Pierre" uniqKey="Brugieres P" first="Pierre" last="Brugières">Pierre Brugières</name></author><author><name sortKey="Capacchione, Daniela" sort="Capacchione, Daniela" uniqKey="Capacchione D" first="Daniela" last="Capacchione">Daniela Capacchione</name></author><author><name sortKey="Itti, Laurent" sort="Itti, Laurent" uniqKey="Itti L" first="Laurent" last="Itti">Laurent Itti</name></author><author><name sortKey="Maison, Patrick" sort="Maison, Patrick" uniqKey="Maison P" first="Patrick" last="Maison">Patrick Maison</name></author><author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name></author><author><name sortKey="Meignan, Michel" sort="Meignan, Michel" uniqKey="Meignan M" first="Michel" last="Meignan">Michel Meignan</name></author></analytic><series><title level="j">Nuclear medicine communications</title><idno type="eISSN">1473-5628</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Dopamine Plasma Membrane Transport Proteins (analysis)</term><term>Dopamine Plasma Membrane Transport Proteins (metabolism)</term><term>Dose-Response Relationship, Drug</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Neostriatum (drug effects)</term><term>Neostriatum (physiopathology)</term><term>Nicotine (administration & dosage)</term><term>Nicotine (therapeutic use)</term><term>Parkinson Disease (diagnostic imaging)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Regression Analysis</term><term>Time Factors</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Tropanes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Nicotine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neostriatum</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Neostriatum</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Nicotine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Dose-Response Relationship, Drug</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Regression Analysis</term><term>Time Factors</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Tropanes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Nicotine therapy might improve the course of Parkinson's disease. This observational study evaluated the performance of dopamine transporter imaging in follow-up patients under nicotine therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19451839</PMID><DateCreated><Year>2009</Year><Month>06</Month><Day>10</Day></DateCreated><DateCompleted><Year>2009</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5628</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>7</Issue><PubDate><Year>2009</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nuclear medicine communications</Title><ISOAbbreviation>Nucl Med Commun</ISOAbbreviation></Journal><ArticleTitle>Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.</ArticleTitle><Pagination><MedlinePgn>513-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MNM.0b013e32832cc204</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Nicotine therapy might improve the course of Parkinson's disease. This observational study evaluated the performance of dopamine transporter imaging in follow-up patients under nicotine therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Six Hoehn and Yahr stage III patients underwent 123I-FP-CIT imaging prior to, 3 months, and 1 year after the onset of nicotine therapy. Nicotine was administered transdermally with increasing daily doses during 3 months (up to 105 mg/day) and decreased progressively. On co-registered magnetic resonance imaging, striatal regions of interest were drawn and binding potentials of 123I-FP-CIT were calculated.Changes in Unified Parkinson's Disease Rating Scale-III over time were compared with binding potentials using regression analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients improved motor scores at 3 months (-65 +/- 22% 'off', -89 +/- 12% 'on') and most received fewer dopaminergic drugs (-30% dosage in average). Motor improvement persisted to a lesser extent at 1 year(-39 +/- 31% 'off', -13 +/- 43% 'on'), partly because one patient stopped the treatment. Interestingly, the decrease in binding potentials (-4.0 +/- 10.5%) was slower than that expected in Parkinsonian patients (usually -10% per year) and was inversely correlated with Unified Parkinson's Disease Rating Scale-III improvement, r= 0.83 'off' and 0.91 'on'.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This observational study emphasizes a potential effect of nicotine therapy on striatal dopamine transporter density, which may be interpreted as direct pharmacological effect or deceleration of neuronal loss.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Itti</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, H. Mondor Hospital, AP-HP, Paris 12 University, Créteil, France. emmanuel.itti@hmn.aphp.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villafane</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Malek</LastName><ForeName>Zoulikha</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Brugières</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Capacchione</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Itti</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Maison</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Cesaro</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Meignan</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nucl Med Commun</MedlineTA><NlmUniqueID>8201017</NlmUniqueID><ISSNLinking>0143-3636</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014326">Tropanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>155797-99-2</RegistryNumber><NameOfSubstance UI="C087552">2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane</NameOfSubstance></Chemical><Chemical><RegistryNumber>6M3C89ZY6R</RegistryNumber><NameOfSubstance UI="D009538">Nicotine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017072" MajorTopicYN="N">Neostriatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014326" MajorTopicYN="N">Tropanes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19451839</ArticleId><ArticleId IdType="doi">10.1097/MNM.0b013e32832cc204</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B42 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000B42 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:19451839
|texte= Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:19451839" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |